Design Controls for Medical Devices 21 CFR Part 820.30

Design controls are the backbone of safe, effective medical device development. They are the systematic set of requirements and activities that ensure a medical device is designed and developed to meet user needs and intended uses, performs as intended under normal and reasonably foreseeable conditions of use, and satisfies all applicable safety and regulatory requirements before it reaches a patient.

21 CFR Part 820.30, the FDA's design control regulation for medical devices, establishes mandatory requirements that apply to every medical device manufacturer subject to the Quality System Regulation. First enacted in 1996 and now codified within the updated Quality Management System Regulation (QMSR) effective February 2026, these requirements have remained the single most consequential quality system element for device manufacturers, consistently ranking as the top cited deficiency area in FDA CDRH inspections for over two decades.

This white paper provides a comprehensive, SEO-optimized, clause-by-clause guide to 21 CFR Part 820.30 design controls. It covers every regulatory requirement from design planning through the Design History File, explains the Design Control V-Model, maps the obligations to ISO 13485:2016 and EU MDR 2017/745, identifies the most common compliance failures, and demonstrates how Cloudtheapp's AI-powered cloud QMS delivers the technology infrastructure needed to build, maintain, and continuously improve a fully compliant design control program.

FDA CDRH data consistently shows design control violations as the single most frequently cited deficiency in medical device Quality System inspections. Between 2022 and 2025, design control observations appeared in more than 55% of all device manufacturer Form 483s. The most cited sub-elements: design validation (820.30(g)), design inputs (820.30(c)), and design changes (820.30(i)).